IRIS - Res&Arch Institutional Research Information System - Research & Archive

TIACCI, Enrico
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.551
AS - Asia 2.771
EU - Europa 2.743
SA - Sud America 454
AF - Africa 64
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 5
Totale 9.595
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.450
SG - Singapore 1.296
IT - Italia 811
IE - Irlanda 419
CN - Cina 363
BR - Brasile 362
RU - Federazione Russa 334
HK - Hong Kong 306
VN - Vietnam 298
UA - Ucraina 247
DE - Germania 175
FR - Francia 156
FI - Finlandia 150
SE - Svezia 148
KR - Corea 99
GB - Regno Unito 88
BD - Bangladesh 79
IN - India 76
NL - Olanda 53
TR - Turchia 47
CA - Canada 43
IQ - Iraq 36
AR - Argentina 32
MX - Messico 32
PL - Polonia 32
AT - Austria 24
JP - Giappone 24
PK - Pakistan 24
BE - Belgio 22
UZ - Uzbekistan 19
CZ - Repubblica Ceca 18
ES - Italia 17
SA - Arabia Saudita 16
CH - Svizzera 15
EC - Ecuador 15
ZA - Sudafrica 15
CO - Colombia 14
MA - Marocco 12
VE - Venezuela 12
ID - Indonesia 11
PE - Perù 9
PH - Filippine 9
JO - Giordania 8
CL - Cile 7
EG - Egitto 6
GR - Grecia 6
KZ - Kazakistan 6
LB - Libano 6
CR - Costa Rica 5
ET - Etiopia 5
OM - Oman 5
PA - Panama 5
AU - Australia 4
BG - Bulgaria 4
DZ - Algeria 4
IL - Israele 4
KE - Kenya 4
KG - Kirghizistan 4
MY - Malesia 4
NP - Nepal 4
AL - Albania 3
AZ - Azerbaigian 3
BH - Bahrain 3
CI - Costa d'Avorio 3
DO - Repubblica Dominicana 3
IR - Iran 3
JM - Giamaica 3
LT - Lituania 3
RO - Romania 3
XK - ???statistics.table.value.countryCode.XK??? 3
AO - Angola 2
BB - Barbados 2
CG - Congo 2
EU - Europa 2
GE - Georgia 2
HN - Honduras 2
HR - Croazia 2
HU - Ungheria 2
KW - Kuwait 2
LK - Sri Lanka 2
LV - Lettonia 2
LY - Libia 2
MD - Moldavia 2
NE - Niger 2
PS - Palestinian Territory 2
PT - Portogallo 2
QA - Qatar 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BY - Bielorussia 1
CV - Capo Verde 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
DK - Danimarca 1
DM - Dominica 1
GD - Grenada 1
Totale 9.579
Salva come PNG Salva come JPEG
Città #
Singapore 896
San Jose 447
Dublin 419
Chandler 410
Perugia 376
Hong Kong 305
Ashburn 250
San Mateo 223
Boardman 157
Santa Clara 139
Dong Ket 132
Moscow 132
Jacksonville 110
Lauterbourg 106
Seoul 99
Altamura 95
Medford 92
Princeton 90
Ann Arbor 77
Beijing 77
Lawrence 73
New York 67
Munich 64
Wilmington 64
Andover 61
Dallas 58
The Dalles 55
Ho Chi Minh City 54
Helsinki 48
Rome 47
Los Angeles 46
Des Moines 44
São Paulo 42
Amsterdam 39
Turku 36
Hanoi 35
Piscataway 29
Izmir 26
Saint Petersburg 25
Frankfurt am Main 24
Nuremberg 24
Brussels 22
Houston 22
Redmond 22
Orem 21
Tokyo 21
Montreal 20
Norwalk 19
London 17
Woodbridge 17
Brooklyn 16
Warsaw 16
Chicago 15
Chennai 14
Belo Horizonte 13
Poplar 13
San Francisco 13
Stockholm 13
Tashkent 13
Manchester 12
Mexico City 12
San Paolo di Civitate 12
Baghdad 11
Johannesburg 11
Atlanta 10
Redwood City 10
Rio de Janeiro 10
Shanghai 10
Terni 10
Haiphong 9
Jeddah 9
Phoenix 9
Porto Alegre 9
Recife 9
Toronto 9
Boston 8
Brno 8
Columbus 8
Denver 8
Guayaquil 8
Todi 8
Amman 7
Barnet 7
Bologna 7
Council Bluffs 7
Curitiba 7
Da Nang 7
Dhaka 7
Lahore 7
Milan 7
Mumbai 7
Olomouc 7
Falkenstein 6
Falls Church 6
Guangzhou 6
Hefei 6
Hải Dương 6
Jakarta 6
Vienna 6
Caracas 5
Totale 6.234
Salva come PNG Salva come JPEG
Nome #
Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells 178
Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? 162
Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification 143
ARSENIC TRIOXIDE AND ALL-TRANS-RETINOIC ACID TARGET NPM1 MUTANT ONCOPROTEIN LEVELS AND INDUCE APOPTOSIS IN NPM1-MUTATED AML CELLS 143
Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial 143
Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma 140
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia 130
Improved achiral and chiral hplc-uv analysis of ruxolitinib in two different drug formulations 130
Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma 126
Choroidal vasculature analysis in MEK inhibitor-associated retinopathy 124
Genomics of Hairy cell leukemia 120
Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance 118
A microRNA signature specific for hairy cell leukemia and associated with modulation of the MAPK-JNK pathways. 117
High-Risk Clonal Hematopoiesis as the Origin of AITL and NPM1-Mutated AML 116
Aberrant somatic hypermutation in tumor cells of nodular lymphocyte-predominant and classical Hodgkin's lymphoma. 114
Absence of BRAF-V600E in the human cell lines BONNA-12, ESKOL, HAIR-M, and HC-1 questions their origin from hairy cell leukemia. 112
Constant Activation of the RAF-MEK-ERK Pathway As a Diagnostic and Therapeutic Target in Hairy Cell Leukemia. 110
Dissecting Clonal Hematopoiesis in Tissues of Classical Hodgkin Lymphoma Patients 109
BRAF mutations in hairy-cell leukemia. 108
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype 108
THE BRAF-MEK-ERK PATHWAY IN HAIRY CELL LEUKEMIA: A COMPREHENSIVE DISSECTION IN PRIMARY LEUKEMIC CELLS OF ITS BIOLOGICAL AND THERAPEUTIC RELEVANCE 108
Blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia: a shared clonal origin 108
Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML 107
Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia 106
Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma. 106
Acute myeloid leukemia development soon after anti-CD19 chimeric antigen receptor T-cell infusion in a patient with refractory diffuse large B-cell lymphoma and pre-existing clonal hematopoiesis 104
Tumor protein D52 (TPD52): a novel B-cell/plasma-cell molecule with unique expression pattern and Ca(2+)-dependent association with annexin VI. 104
A case of concomitant chronic lymphocytic leukaemia and hairy cell leukaemia evaluated for IGHV-D-J rearrangements and BRAF-V600E mutation: lack of evidence for a common origin 104
Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). 104
Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype 103
Biological and therapeutic relevance of the BRAF-MEK-ERK pathway in hairy cell leukemia 102
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation 101
Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia 100
Aberrant subcellular expression of nucleophosmin and NPM-MLF1 fusion protein in acute myeloid leukaemia carrying t(3;5): a comparison with NPMc+ AML. 100
The human NPM1 mutation A perturbs megakaryopoiesis in a conditional mouse model. 99
The NPM1 wild-type OCI-AML2 and the NPM1-mutated OCI-AML3 cell lines carry DNMT3A mutations. 98
ALK signaling and target therapy in anaplastic large cell lymphoma 97
Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML 97
Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia. 96
The gene mutation landscape of acute myeloid leukemia cell lines and its exemplar use to study the BCOR tumor suppressor 95
A BRAF-mutated case of hairy cell leukaemia lacking Annexin-A1 expression 95
Frequent traces of EBV infection in Hodgkin and non-Hodgkin lymphomas classified as EBV-negative by routine methods: expanding the landscape of EBV-related lymphomas [Tiacci and Lazzi are co-senior authors] 95
How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors 95
Evolving concepts in the pathogenesis of hairy-cell leukaemia. 94
Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma. 94
A curious novel combination of nucleophosmin (Npm1) gene mutations leading to aberrant cytoplasmic dislocation of npm1 in acute myeloid leukemia (aml) 93
Artificial Intelligence-Powered Molecular Docking and Steered Molecular Dynamics for Accurate scFv Selection of Anti-CD30 Chimeric Antigen Receptors 93
Whole-Exome Sequencing Identifies Recurrent Mutations of BCOR in Acute Myeloid Leukemia with Normal Karyotype 92
Aspects of gene expression in B cell lymphomas 91
BRAF V600E mutation in hairy cell leukemia: From bench to bedside 91
Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study 90
Mutational landscape of AML with normal cytogenetics: biological and clinical implications 90
Primary Burkitt's lymphoma of bladder in patient with AIDS. 88
SARS-CoV-2 infection and vaccination in patients with hairy-cell leukaemia 87
Overlapping features of therapy-related and de novoNPM1-mutated AML 86
Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications 86
IRTA1 is selectively expressed in nodal and extranodal marginal zone lymphomas. 84
Identification and Characterization of Novel Rare Nucleophosmin (NPM1) Gene Mutations in Acute Myeloid Leukemia (AML) By a Combinatorial Approach of Immunohistochemistry and Molecular Analyses 84
Immunohistochemical surrogates for genetic alterations of CCDN1, PML, ALK, and NPM1 genes in lymphomas and acute myeloid leukemia. 82
Hairy Cell Leukemia Biomarkers and Methods of Using Same 82
One disease, two faces: clonally-related AML and MPDCP with skin involvement 81
Defining TCRγδ lymphoproliferative disorders by combined immunophenotypic and molecular evaluation 80
Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors 79
Identification of novel STAT5B mutations and characterization of TCRβ signatures in CD4+ T-cell large granular lymphocyte leukemia 79
PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia 77
The genetics of nodal marginal zone lymphoma 77
New treatment options in hairy cell leukemia with focus on BRAF inhibitors 77
T-bet-positive and IRTA1-positive monocytoid B cells differ from marginal zone B cells and epithelial-associated B cells in their antigen profile and topographical distribution. 76
Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. 75
New classification of acute myeloid leukemia and precursor-related neoplasms: changes and unsolved issues. 75
Haploidentical peripheral-blood stem-cell transplantation for ALK-positive anaplastic large-cell lymphoma. 75
[Global gene expression analysis and novel signalling pathways in Hodgkin lymphoma] 75
Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma. 75
Anaplastic large-cell lymphoma 74
Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. 72
HAPLOIDENTICAL TRANSPLANTATION WITH TREG-TCON ADOPTIVE IMMUNOTHERAPY FOR THE CURE OF ACUTE MYELOID LEUKEMIA WITH HIGH-RISK CYTOGENETICS 71
The BRAF-V600E mutation in hematological malignancies: a new player in hairy cell leukemia and Langerhans cell histiocytosis. 71
Identification of a new subclass of ALK negative ALCL expressing aberrant levels of ERBB4 transcripts 71
Mutations in the genes coding for the NF-κB regulating factors IκBα and A20 are uncommon in nodular lymphocyte-predominant Hodgkin's lymphoma. 69
The Kruppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma 68
THE BRAF INHIBITOR VEMURAFENIB IS SAFE AND HIGHLY EFFECTIVE IN REFRACTORY AND RELAPSED HAIRY CELL LEUKEMIA: RESULTS OF THE HCL-PG01 PHASE-2 ITALIAN CLINICAL TRIAL 67
Starry sky pattern predicts RAS pathway activation in NPM1‐mutated acute myeloid leukemia 66
Correction to: One disease, two faces: clonally-related AML and MPDCP with skin involvement 64
The authors reply 64
High expression of several tyrosine kinases and activation of the PI3K/AKT pathway in mediastinal large B cell lymphoma reveals further similarities to Hodgkin lymphoma. 63
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia 63
Lymphoma 62
Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 61
The corepressors BCOR and BCORL1: two novel players in acute myeloid leukemia. 61
Expression of the IRTA1 receptor identifies intraepithelial and subepithelial marginal zone B cells of the mucosa-associated lymphoid tissue (MALT). 60
Venetoclax in Relapsed or Refractory Hairy-Cell Leukemia 58
IRTA1+ monocytoid B cells in reactive lymphadenitis show a unique topographic distribution and immunophenotype and a peculiar usage and mutational pattern of IgVH genes. 58
An unusual form of BRAF‐V600E mutated hairy cell neoplasm with clinical resistance to BRAF inhibition: Challenging precision medicine 57
Subclonal evolution of a classical Hodgkin lymphoma from a germinal center B-cell-derived mantle cell lymphoma. [Tiacci, Mecucci and Kueppers are co-senior authors] 56
Transformation of IGHV4-34+ hairy cell leukaemia-variant with U2AF1 mutation into a clonally-related high grade B-cell lymphoma responding to immunochemotherapy 55
Hairy cell leukaemia mimicking multiple myeloma 55
Hairy cell leukaemia with low CD103 expression: A rare but important diagnostic pitfall 52
SAVI: a statistical algorithm for variant frequency identification. 52
Correction: Frequent traces of EBV infection in Hodgkin and non-Hodgkin lymphomas classified as EBV-negative by routine methods: expanding the landscape of EBV-related lymphomas 50
B-cell receptor reactivity against Rothia mucilaginosa in nodular lymphocyte-predominant Hodgkin lymphoma 50
Totale 9.053
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.401
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.401
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021138 0 0 0 0 0 0 0 0 0 0 0 138
2021/2022936 16 159 4 22 25 8 12 237 59 71 197 126
2022/20231.418 98 268 17 115 101 146 4 49 527 37 43 13
2023/2024607 35 41 43 13 8 9 142 3 51 19 125 118
2024/20251.738 64 174 60 72 236 90 108 123 323 101 250 137
2025/20263.819 278 207 155 364 654 355 656 213 430 305 153 49
Totale 9.958